Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06277934 · ClinicalTrials.gov registry record · Phase 2
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities
A Phase 2 study, sponsored by Regor Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT06277934: Completed Phase 2 study, sponsored by Regor Pharmaceuticals.
NCT06277934 is a Phase 2 study that has completed, run by Regor Pharmaceuticals. The registered enrollment target is 73 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06277934, a Phase 2 study, has completed, sponsored by Regor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
Interventions
- DRUG Placebo
- DRUG RGT001-075
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2024-03-08 |
| Est. Completion | 2024-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06277934
The ClinicalTrials.gov registry entry for NCT06277934 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regor Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06277934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06277934 about?
NCT06277934 is a clinical study titled "A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities". The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
What is the current status of trial NCT06277934?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2024-03-08. Estimated completion is 2024-08-13.
What interventions are being tested in trial NCT06277934?
The interventions under investigation include: Placebo (DRUG), RGT001-075 (DRUG).
Who is sponsoring clinical trial NCT06277934?
This trial is sponsored by Regor Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.